# QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

> **NCT05446883** · PHASE3 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 498 (estimated)

## Conditions studied

- METASTATIC CERVICAL CANCER

## Interventions

- **DRUG:** QL1706
- **DRUG:** Placebo
- **DRUG:** Paclitaxel injection
- **DRUG:** Cisplatin/Carboplatin

## Key facts

- **NCT ID:** NCT05446883
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-23
- **Primary completion:** 2024-09-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 498 (ESTIMATED)
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05446883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05446883, "QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05446883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*